HSR25-159: Real-World Effectiveness of First-Line Osimertinib for Patients in the US With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer Who Were Eligible for Medicare

Authors: Pritesh S. Karia, Yan Kwan Lau, Darren Thomas, Rachel Salomonsen, Rahul Shenolikar

Published: 2025-03-28

DOI: 10.6004/jnccn.2024.7278

Source: Full article

No abstract found.